Methodology and data sources

This tracker uses a five-tier source hierarchy. Tier one is SEC EDGAR filings for the three public comparables: Acadia Healthcare (NASDAQ: ACHC), LifeStance Health (NASDAQ: LFST), and Universal Health Services (NYSE: UHS). Tier two is federal primary sources: the Federal Register for the Mental Health Parity and 42 CFR Part 2 final rules, the Department of Justice and Drug Enforcement Administration for enforcement actions, the Department of Labor for parity guidance, SAMHSA for prevalence and facility-census data, HRSA for workforce projections, CMS for Innovation Center model awards and National Health Expenditure data, and the FCC for 988 Lifeline rules. Tier three is sponsor portfolio pages, which we treat as authoritative for current ownership but acknowledge can lag transaction dates. Tier four is industry trade press of record, with Behavioral Health Business as the primary outlet, and tier five is investment-bank commentary from Mertz Taggart, FOCUS Investment Banking, Braff Group, Provident Healthcare Partners, and VMG Health for transaction-level color and multiple ranges.

The verification window is January 1, 2024 to June 16, 2026. Inclusion criteria: the platform must operate primarily in the United States, must serve adult or adolescent mental health, SUD, or eating-disorder populations, and must have a current sponsor or parent identified to a primary source. We exclude applied behavior analysis (ABA) and autism services, which are covered in a forthcoming sibling tracker. We also exclude intellectual and developmental disability (I/DD) consolidators, ambulatory surgery-anchored psychiatry, and pure consumer-app mindfulness companies that do not deliver clinical care under a state licensure framework.

Sponsor-misattribution risk: this brief identified six widely repeated sponsor errors in 2024 to 2026 trade coverage. Pyramid Healthcare is held by Nautic Partners, not Wellspring Capital. Eating Recovery Center is held by Apax Funds plus Oak HC/FT since October 2021, not by CCMP Capital plus Trilantic. Sandstone Care is held by The Vistria Group since June 2022, not by Greenbriar Equity. Embark Behavioral Health is held by Consonance Capital Partners since late 2022, not by Flexpoint Ford. Springstone is owned by Lifepoint Health (the Apollo-controlled hospital operator), not by Petra Capital, which separately runs Acute Behavioral Health. Refresh Mental Health is owned by UnitedHealth Group’s Optum, not by Kelso & Company (Kelso exited in early 2022). Each correction is sourced to a primary citation in the rows that follow.

Macro spine: why behavioral health attracts private equity in 2026

The behavioral-health roll-up thesis rests on three load-bearing facts: a treatment gap that has not narrowed, federal regulatory infrastructure that has matured substantially since 2022, and a workforce supply curve that lags demand by enough to make capital, geography, and credentialing the rate-limiting steps for any platform operator.

Prevalence comes from the SAMHSA 2024 National Survey on Drug Use and Health (NSDUH), released July 28, 2025. In 2024, 23.4 percent of US adults (61.5 million) experienced any mental illness, 5.6 percent (14.6 million adults) experienced serious mental illness, and 16.8 percent of people aged 12 and over (about 48.4 million) met criteria for a substance use disorder. Among adults with any mental illness, 31.5 percent also met SUD criteria, the co-occurring population that drives demand for integrated care. The treatment gap remains roughly 80 percent of those who needed SUD treatment in 2024 did not receive it. Only 3.5 percent of the 12-plus population received any SUD treatment in 2024, down from 4.6 percent in 2023, a 1.1-percentage-point drop that SAMHSA’s release attributed to a combination of post-pandemic care-seeking shifts and continued workforce constraints.

Facility supply is mapped in SAMHSA’s 2024 National Substance Use and Mental Health Services Survey (N-SUMHSS) annual report: 21,205 eligible substance-use and mental-health treatment facilities operate in the United States and territories. That number includes nonprofit, government, and for-profit operators across inpatient, residential, partial-hospitalization, intensive-outpatient, outpatient, telehealth-only, and detox license categories. The 2024 National Directory of Mental Health Treatment Facilities is the underlying federal roster used for parity reporting.

Spending sits inside the largest healthcare system in the world. CMS National Health Expenditure data show US health spending reached $5.3 trillion in 2024, growing 8.2 percent. Medicare spending grew 7.8 percent to $1,118.0 billion in 2024. Medicaid spending grew 6.6 percent to $931.7 billion in 2024 (Healthcare Dive). A clean line-item federal behavioral-health spending figure is not published as a single CMS series; the relevant decomposition has to be assembled from NHE actuarial estimates and MACPAC Medicaid behavioral-health share each year. Federal Medicaid spending alone reached nearly $909 billion in FFY2024 with managed care at $517.5 billion FFY2024 and $550.5 billion FFY2025; Health Management Associates notes that more than half of states implemented FFS rate increases for outpatient behavioral-health providers in FY2024 and roughly half again in FY2025. KFF tracks behavioral health as a stated top utilization driver in state Medicaid commentary.

The 988 Suicide and Crisis Lifeline is now a national crisis-services backbone. NAMI reports 988 received more than 8 million contacts (calls, texts, chats, ASL) in 2025. Congress appropriated $520 million for the 988 Lifeline in FY2025, per GAO-26-107915, with SAMHSA having received $1.6 billion across FY21 to FY24 and awarded $1.2 billion to recipients. SAMHSA published a $231 million funding opportunity to administer the Lifeline in January 2026. As of June 2025, twelve states had enacted a recurring 988 telecom fee and five had recurring state appropriations (NAMI 988 Crisis Response State Legislation Map). The FCC’s georouting rules adopted October 2024 required nationwide wireless carriers to deliver 988 calls to the geographically appropriate crisis center by January 13, 2025. The federal LGBTQI+ Youth Subnetwork was shut down July 17, 2025.

The Opioid Settlement national pool totals approximately $57.7 billion across all 50 states and territories as of December 2025, per Congressional Research Service LSB11270 and the National Opioid Settlement allocation site. The distributor settlement with McKesson, Cardinal Health, and AmerisourceBergen is about $21 billion. The Janssen / Johnson & Johnson settlement is $5 billion. Kroger settled on March 22, 2024 for approximately $1.4 billion. 2025 add-on settlements with Purdue Pharma plus a generic-manufacturer group (Alvogen, Amneal, Apotex, Hikma, Mylan / Viatris, Sun, Zydus) were finalized through state attorneys general (see Maryland Office of Overdose Response). State plans typically direct 60 to 70 percent of disbursed funds to treatment-related uses including MAT and MOUD capacity.

Suicide rates provide the demand-pull baseline. The CDC NCHS Data Brief No. 509, September 2024, reports the final 2023 age-adjusted suicide rate at 14.1 per 100,000, statistically unchanged from 14.2 in 2018. The male rate was 22.7 in 2023 (23.0 in 2022). The female rate was 5.9 in both 2022 and 2023. Suicide was the 11th leading cause of death in the United States in 2023. The female 75-and-older rate rose from 4.6 to 5.1, and the male 75-and-older rate fell from 43.9 to 40.7, between 2022 and 2023.

By construction, this is the largest US healthcare service-delivery roll-up category after dental, veterinary, and home-health by addressable need. Three structural tailwinds frame the 2024 to 2026 deal-flow set. First, stigma compression: 988 reach, employer EAP normalization, and consumer-app household penetration have moved adult-population utilization rates upward in commercial books. Second, parity rule enforcement (discussed in the next section) creates the possibility, if not yet the realization, of upward reimbursement pressure for outpatient mental-health services billed against commercial plans. Third, MAT and MOUD demand continues to compound as opioid-settlement dollars hit state treatment lines and Section 1115 SUD waivers expand IMD-eligible bed supply.

The Mental Health Parity Final Rule (Sept 9, 2024) and the May 12, 2025 enforcement pause

Sibling healthcare tracker: behavioral health and ortho MSO economics share the specialty roll-up pattern but diverge sharply on procedural intensity and ASC dynamics. 14-platform ortho map in the 2026 Orthopedic PE Roll-Up Tracker.

Sibling healthcare tracker: behavioral health and GI MSO economics share the procedural-specialty roll-up pattern but diverge sharply on payor mix and regulatory backdrop. 15-platform GI map in the 2026 Gastroenterology PE Roll-Up Tracker.

Sibling healthcare tracker: behavioral health and ophthalmology share the outpatient-MSO PE thesis but diverge sharply on payor mix and regulatory backdrop. 22-platform ophth map in the 2026 Ophthalmology PE Roll-Up Tracker.

Sibling healthcare tracker: PT and behavioral health share the outpatient-MSO PE thesis but diverge on payor mix, parity rule, and federal enforcement profile. Full primary-source map of 18 PT platforms in the 2026 Physical Therapy PE Roll-Up Tracker.

Closest sibling tracker: ABA therapy is structurally adjacent to behavioral health but with distinct cap tables (BlueSprig/KKR, Centria/THL, Action Behavior/Charlesbank) and a different federal enforcement profile. The CARD bankruptcy of June 2023 still resets PE underwriting models in 2026. Full primary-source map of 15 platforms in the 2026 ABA Therapy PE Roll-Up Tracker.

On September 9, 2024 the Departments of Labor, Health and Human Services, and Treasury issued the final rule “Requirements Related to the Mental Health Parity and Addiction Equity Act,” published in the Federal Register September 23, 2024 at 89 FR 77586, effective November 22, 2024. The DOL fact sheet describes a phased compliance schedule: certain provisions effective January 1, 2025, additional non-quantitative-treatment-limitation (NQTL) comparative-analysis content and network-composition data requirements effective January 1, 2026.

On January 17, 2025 the ERISA Industry Committee (ERIC) sued to block the rule. On May 12, 2025 the Departments announced a non-enforcement policy for portions of the NQTL final regulation pending reconsideration (DOL statement; Groom Law Group summary; IFEBP). MHPAEA enforcement nevertheless remains a stated 2026 DOL priority per PSCA reporting from former EBSA leadership.

What “rerate” was supposed to mean: under a fully enforced final rule, commercial group health plans would have had to demonstrate, with specific quantitative comparative analyses, that NQTLs applied to mental-health and SUD benefits are no more restrictive than NQTLs applied to medical and surgical benefits. The practical expectation in the platform-investor community was that prior-authorization friction would compress, network-adequacy standards would tighten, and effective reimbursement per service for outpatient mental health would lift, particularly for psychiatry and psychotherapy provided through national in-network platforms (LifeStance, Refresh, Mindpath, Talkiatry’s in-network model).

What actually happened: the May 2025 enforcement pause stalled the catalyst, but private buyers continued to price as if the rerate were live, creating a mispricing dynamic. Mertz Taggart’s Q4 2025 report reports multiples “stable” rather than expanding, with valuations widening between premium and distressed assets (“flight to quality”). The parity-driven valuation lift remains an option, not a fact, through at least 2026. For diligence on outpatient mental-health platforms in 2026, modeling parity uplift as a probability-weighted scenario rather than a base case is the disciplined posture.

The Cerebral and Done DOJ probe effect on telehealth mental-health PE thesis

Two enforcement matters in 2024 to 2026 permanently shifted the underwriting standard for telehealth mental-health platforms that prescribe controlled substances. The first is Cerebral. In November 2024 Cerebral entered a $3.65 million non-prosecution agreement with the Eastern District of New York US Attorney’s Office over allegations of encouraging Adderall over-prescription between 2019 and 2022 (Healthcare Dive). An earlier $7 million joint FTC and DOJ settlement (Fierce Healthcare) resolved separate allegations on user-data sharing and cancellation practices. Founder Kyle Robertson’s civil litigation remains active. Cerebral’s investor syndicate (Silver Lake Waterman, Oak HC/FT, Access Industries, Bill Ackman) has been opaque since the 2023 down round.

The second is Done Global. In June 2024, founder Ruthia He and clinical president David Brody were arrested in the Department of Justice’s first criminal prosecution of a digital-health controlled-substance distributor. The indictment cited approximately $100 million in revenue and 40 million pills (Adderall and other stimulants). In December 2025 a systemic-fraud indictment was unsealed in the Northern District of California. The founder was subsequently convicted of Adderall fraud-scheme charges. Ropes & Gray’s analysis argues the Done outcome signals expanded criminal risk across telehealth controlled-substance prescribing.

The DEA, meanwhile, extended the COVID-19 telemedicine flexibilities for prescribing controlled substances through December 31, 2026 (DEA press release, December 31, 2025; Federal Register). The DEA and HHS published two final rules on January 17, 2025: “Expansion of Buprenorphine Treatment via Telemedicine Encounter” and “Continuity of Care via Telemedicine for Veterans Affairs Patients,” effective December 31, 2025 (Holland & Knight; McDermott+). The DEA said the extension provides time to finalize a permanent telemedicine prescribing rule.

What changed in diligence: quality-of-earnings adders on telehealth mental-health platforms now include controlled-substance prescribing audits, Drug Enforcement Administration registration reviews per prescriber and per state, prior-authorization friction modeling on stimulant and opioid prescriptions, and counsel-led document holds covering at least 36 months. Sponsors that previously treated stimulant ADHD telehealth as a normal-course outpatient line now run separate criminal-risk diagnostics. Talkiatry and Two Chairs, which raised capital through 2024 to 2026 despite the chill, both deliberately position around full-stack in-network psychiatry rather than direct-to-consumer ADHD prescribing. That positioning is not a marketing posture; it is the diligence dividing line that allowed those rounds to clear.

The Optum effect on outpatient mental health (Refresh Mental Health, Jan 2022)

Optum acquired Refresh Mental Health from Kelso & Company in early 2022. The acquisition made UnitedHealth Group’s care-delivery arm the operator of the single largest US outpatient mental-health platform by site count: 300-plus sites across 37 states, 1,500-plus employees, with continued tuck-in activity through CARE Counseling (Behavioral Health Business, May 30, 2024, citing Optum president Heather Cianfrocco’s wait-time strategy commentary).

Why this is under-tracked: most market participants still treat Refresh as a Kelso-era asset in 2025 to 2026 press references, and bank-led roll-up theses for outpatient mental health typically benchmark against LifeStance (public), Mindpath (Centerbridge plus Leonard Green), or Sero Mental Health (Lindsay Goldberg) without acknowledging that the largest scaled asset sits inside a payor-owned strategic, not a PE platform.

Implication for next-buyer math: the top-tier outpatient mental-health exit market is structurally smaller than the platform count suggests. If you remove Refresh from the addressable buyer pool for sponsor-to-sponsor exits, the universe of buyers capable of absorbing a $25M-plus EBITDA outpatient mental-health platform contracts to LifeStance (constrained by public-market discipline and balance-sheet capacity), Optum itself (which buys but at strategic multiples it sets), regional sponsor-backed platforms that have not yet reached national scale, and a small set of growth-equity buyers focused on virtual-first models. The mid-market exit assumption that “there is always another sponsor” becomes weaker once Refresh is correctly classified as a strategic, not a sponsor asset.

42 CFR Part 2 final rule (Feb 16, 2024, enforcement Feb 16, 2026)

SAMHSA published the final rule “Confidentiality of Substance Use Disorder Patient Records” on February 16, 2024 at 89 FR 12472, effective April 16, 2024 with a two-year compliance period. Active enforcement began February 16, 2026 (Hall Render summary). The major changes align consent and re-disclosure with HIPAA per CARES Act Section 3221, create a safe harbor for investigative agencies that obtain Part 2 records without first obtaining a court order, and require separate consent for use and disclosure of SUD counseling notes (American Psychiatric Association).

What this does to SUD platform M&A: data-room mechanics now have to include explicit Part 2 consent inventories at the patient level, sample audit results on re-disclosure logs, EHR configuration documentation showing how SUD counseling-note flags are enforced, and a written compliance policy aligned to the 2026 enforcement effective date. Buyers run pre-LOI Part 2 audits as standard practice in 2026 because a misconfigured EHR can expose the post-close operator to enforcement liability. Platforms that integrated under HIPAA-only configurations during the two-year compliance ramp face retroactive review.

Why this matters for valuation: the additional cost of Part 2 compliance is small at platform scale but meaningful at single-site or sub-scale operator level. The rule consolidates the platform advantage. A 138-location operator like Pinnacle Treatment Centers or a 280-plus-facility operator like BayMark amortizes Part 2 governance across thousands of patient encounters; a three-site independent operator does not. This is a quiet roll-up tailwind that did not exist in the same operationalized form before the 2026 enforcement effective date.

IMD exclusion partial repeal and Section 1115 SUD / SMI waiver count

The Further Consolidated Appropriations Act of 2024, signed in March 2024, softened the Institutions for Mental Diseases (IMD) exclusion by allowing federal Medicaid match for certain SUD services in IMDs (NABH IMD Exclusion Fact Sheet, Summer 2024; CRS IF10222). The historical IMD exclusion barred federal Medicaid payment for services in inpatient psychiatric facilities with more than 16 beds for adults aged 21 to 64; the partial repeal opens federal match for a subset of SUD services in qualifying IMDs, contingent on state implementation under Section 1115 demonstration authority.

As of January 2025, 36 states plus the District of Columbia had an approved Section 1115 SUD waiver. As of July 2025, 11 states had approved Section 1115 SMI waivers and 7 had pending applications (KFF Medicaid Waiver Tracker; KFF state options). By October 1, 2025, SUD-waiver states are required to use evidence-based individual placement criteria and to have a compliance review process for IMD treatment (Association for Behavioral Health and Wellness IMD Brief 2025).

The CMS Innovation in Behavioral Health (IBH) Model is a state-Medicaid-anchored seven-year cooperative agreement. On January 1, 2025, CMS awarded cohort 1 cooperative agreements to Michigan, New York, and South Carolina, with up to 8 states across the life of the model and up to $7.5 million per state (CMS IBH page; National Association of Counties; Commonwealth Fund). IBH integrates physical and behavioral health at the community-based provider level, which over a multi-year horizon shapes the value of integrated FQHC and CCBHC roll-ups versus stand-alone behavioral platforms.

Medicare added 2025 behavioral-health coverage expansions including new safety-planning intervention codes (20-minute increments, telehealth-eligible) and Medicare coverage of FDA-approved digital mental-health devices (CMS blog; Moss Adams summary). These are small dollar additions individually but they signal a structural shift toward Medicare-recognized digital behavioral-health interventions.

State variability matters for any platform model. The 36-state-plus-DC Section 1115 SUD waiver count masks substantial variation in how states implement evidence-based individual placement criteria, IMD bed eligibility, and managed-care carve-in versus carve-out structures. California operates the CalAIM transformation with a separate set of community-supports and enhanced-care-management benefits that fund SUD and SMI services through managed-care plans; New York runs the Behavioral Health Home Plus pilot under its 1115; Pennsylvania runs the HealthChoices behavioral managed care structure; Texas operates with delivery-system reform incentive payments retired in 2024 and a value-based approach in transition. Platforms with multi-state footprints have to track these structures at the contract level, not the headline level. KFF’s tracker is the canonical reference, but the SMI waiver subset (11 approved, 7 pending as of July 2025) is the more diligence-relevant variable for inpatient-psych platform underwriting.

The opioid settlement allocation logic adds another layer. Each state allocates settlement dollars under the National Opioid Settlement framework with a state-specific advisory council; some states (Pennsylvania, Ohio, North Carolina, West Virginia, Tennessee, Kentucky, Indiana) direct meaningful percentages to opioid-treatment-program capacity and Naloxone distribution. Platforms that contract with state and county recipients of settlement funds can model an additional commercial revenue layer that did not exist in 2019. The settlement reporting infrastructure improved measurably in 2024 to 2025 as the Johns Hopkins Bloomberg School of Public Health Opioid Settlement Tracker and the KFF Settlement Tracker matured. The reporting infrastructure also reveals geographies where settlement dollars are flowing to law-enforcement and supply-side interdiction rather than treatment, which is a negative signal for platform expansion in those counties.

Active 2024 to 2026 PE platforms (the big table)

This is the central inventory. Every row was verified to a primary source in the 2024 to 2026 window. Confidence ratings reflect sponsor identity, scale claims, and 2024 to 2026 deal-flow verification. Where the research brief showed a sponsor misattribution, the corrected sponsor is in the row and the misattribution is flagged in the Key Deals cell.

The table covers 28 distinct active PE-backed platforms plus 4 strategic / nonprofit operators included for completeness because their behavior shapes the addressable buyer pool. Multiple-platform Nautic Partners exposure (Pyramid, Odyssey, Sagent, Advantage Healthcare Services) and multiple-platform Vistria exposure (BHG, Sandstone, Advanced Recovery Systems) are the two largest sponsor concentrations as of mid-2026.

Segment-by-segment breakdowns

Inpatient psychiatric

Dominant platforms: Acadia Healthcare (public), UHS behavioral segment (public), Springstone (Lifepoint / Apollo), US HealthVest. Acadia’s 277 facilities with 12,500-plus beds in 40 states plus Puerto Rico per the FY2025 10-K and UHS’s behavioral segment generating $404.5M same-store adjusted EBITDA at 22.3% margin in Q3 2025 anchor the high end of the platform-multiple band. Springstone (18 hospitals plus 35 outpatient sites) and US HealthVest (8 hospitals across IL, WA, IN, GA) sit one step below scale-wise but with comparable per-bed economics. Segment multiple range for scaled inpatient-psych platforms: 10 to 13 times EBITDA per FOCUS December 2025 commentary, with the public peer set anchoring the comp. Regulatory pressure: the Acadia DOJ settlement and three concurrent federal inquiries are a sector-specific overhang that is governance-driven, not asset-class-driven. Sponsor concentration: low (one public, one strategic-PE, one PE-rolled-into-public, one founder). Confidence: HIGH on platform identity and scale; MEDIUM on transaction-specific multiples.

Residential SUD treatment

Dominant platforms: Pyramid Healthcare (Nautic), Advanced Recovery Systems (Vistria), Discovery Behavioral Health (Capital One / HPS post-default), Banyan Treatment Centers (TPG Rise), Bradford Health Services (Lee Equity + Constitution Capital), AMFM Healthcare (New Heritage), First Steps (Avesi), Hazelden Betty Ford (nonprofit). The Q4 2025 mix shows residential SUD demand consolidating into the top quintile of operators that combine multi-state licensure, accreditation, and payer diversification. Pyramid and Advanced Recovery Systems both reportedly on the market per BHB October 15, 2025. Discovery’s lender takeover in February 2026 is the segment’s largest distress event of the cycle. Segment multiple range: 7 to 11 times EBITDA per FOCUS, with the spread widening between premium (Bradford-class, with specialized professional / clinician programs) and distressed assets. Regulatory pressure: 42 CFR Part 2 enforcement (live February 16, 2026), the IMD partial repeal, and the 1115 SUD waiver count. Sponsor concentration: Vistria multi-platform exposure, Nautic multi-platform exposure.

Outpatient mental health

Dominant platforms: Refresh Mental Health (Optum / strategic), LifeStance (public), Mindpath (Centerbridge + Leonard Green), Sero Mental Health (Lindsay Goldberg). Refresh’s 300-plus sites across 37 states make it the largest US outpatient MH operator by site count. LifeStance reported Q1 2026 revenue of $403.5M and 2026 guidance of $1.615B to $1.655B in revenue with $185M to $205M adj EBITDA, implying an adj EBITDA margin around 12%. Mindpath has been a cautionary case study for outpatient MH platform integration with documented layoffs and closures (Stat News; PE Stakeholder Project). Segment multiple range: 9 to 12 times EBITDA for private platforms per FOCUS. LFST trades around the bottom of the platform-tier band. Regulatory pressure: MHPAEA parity enforcement (paused May 2025), commercial-payer NQTL compliance audits, prior-authorization friction modeling. Sponsor concentration: low (one public, one strategic, two PE platforms with different sponsors).

Eating disorder and specialty

Dominant platforms: Eating Recovery Center / Pathlight (Apax + Oak HC/FT), Discovery Behavioral Health (Capital One / HPS post-takeover), Veritas Collaborative, Center for Discovery. ERC’s ~30 centers and tri-modality (residential + day treatment + virtual) plus Pathlight mood / anxiety integration set the asset-class benchmark. Discovery’s lender takeover in February 2026 marked the first material distress in this niche. Segment multiple range: 10 to 15 times EBITDA for scaled, payer-diversified, clinically differentiated assets; the band reflects how scarce true platform-tier eating-disorder assets are. Regulatory pressure: state licensure, particularly for adolescent residential beds; CMS digital MH device coverage on the edges. Sponsor concentration: HIGH (ERC dominates the platform-tier set; Discovery is now lender-controlled, removing it from the standard sponsor exit pool).

OUD and MAT

Dominant platforms: BayMark Health Services (Webster Equity), Crossroads Treatment Centers (Revelstoke + CDPQ), Pinnacle Treatment Centers (Linden), Behavioral Health Group / BHG (Vistria), Recovery Centers of America (Deerfield), Spero Health (GSAM), Pathway Healthcare. BayMark is the largest single OTP operator in the country (102 OTPs across 28 states, 280-plus total facilities) per the Health Affairs February 2025 PE OTP study; Webster has the asset on market a second time at ~$75M marketed EBITDA per BHB. The Senate Markey / Braun March 2024 PE-OTP inquiry hit BayMark, Crossroads, BHG, Pinnacle, and Acadia’s CTC unit. Segment multiple range: 8 to 12 times EBITDA, with the OTP-specific sub-band toward the lower end due to enforcement and reimbursement scrutiny. Regulatory pressure: Markey / Braun continued oversight, false-claims settlements (Crossroads), Health Affairs research on market-level methadone supply effects. Sponsor concentration: high mid-market PE participation. Confidence: HIGH on platform identity; MEDIUM on individual platform multiples given Webster’s second-attempt sale process for BayMark.

IOP and PHP

Dominant platforms: Acadia (PHP within facility footprint), LifeStance (limited IOP), Pyramid (multi-modality), Discovery (tri-modality, lender-controlled), Pathway Healthcare (Spravato + IOP expansion 2025), Mindpath (TMS / Spravato + outpatient). Segment is structurally hybrid; pure-play IOP / PHP platforms are rare because IOP economics typically attach to a larger residential or outpatient platform. Segment multiple range: 9 to 13 times EBITDA for outcomes-driven, payer-diversified assets. Regulatory pressure: CMS Medicare IOP / PHP rate-setting (2024 Medicare expanded IOP coverage in eligible settings). Sponsor concentration: distributed.

Telehealth mental health

Dominant platforms: Talkiatry (a16z, Perceptive, Sofina), Two Chairs (Amplo + Fifth Down + others), Brave Health (Town Hall Ventures), Headspace Health (Blackstone), Cerebral (residual private syndicate), Done (in receivership). Talkiatry’s $210M Series D in February 2026 cleared diligence on the post-Cerebral / post-Done risk standard, which is a signal that in-network, full-stack, non-stimulant-led psychiatry remains fundable. Two Chairs raised $72M in April 2024 (Series C) and continued to expand through 2025. Segment multiple range: 2 to 5 times revenue rather than EBITDA, given lower current profitability and venture / growth-equity buyer base. Regulatory pressure: DEA telemedicine flexibilities (extended through December 31, 2026), DOJ controlled-substance prescribing enforcement (Cerebral, Done), HIPAA + Part 2 + state telehealth practice requirements. Sponsor concentration: venture-equity-dominated; classic PE participation is structurally limited by the EBITDA profile.

Pediatric and adolescent mental health

Dominant platforms: Embark Behavioral Health (Consonance), Sandstone Care (Vistria), Acute Behavioral Health (Petra), Discovery (eating-disorder sub-line). Embark’s Q1 2025 C-suite reset per BHB January 24, 2025 signals operational pressure in adolescent / young-adult residential platforms. Acute Behavioral Health (Petra) added Hallmark Youthcare in July 2022 and continues to build pediatric / adolescent inpatient capacity per Capstone Partners pediatric BH M&A reporting. Segment multiple range: 9 to 13 times EBITDA for scaled adolescent programs with clinical-outcomes data; specialty pediatric is a thin buyer pool. Regulatory pressure: state licensure for adolescent residential beds, NIDA / SAMHSA youth-services scrutiny, allegations of restraint and seclusion practices in trade press. Sponsor concentration: moderate; three named PE platforms plus selected nonprofit and health-system operators.

The adolescent residential sub-segment carries additional litigation and reputational exposure relative to other behavioral-health sub-segments. State attorneys general and federal class-action plaintiffs have increasingly targeted “troubled teen industry” allegations covering programs across the country since 2022. Sponsors underwriting adolescent residential platforms now run a separate insurance and litigation diligence workstream covering general liability coverage limits, allegations history by site, state-licensure compliance, parental-consent documentation, and any pending or threatened class-action exposure. This insurance layer is a multi-million-dollar annual cost at platform scale and was a much smaller line in 2018 to 2020 transactions. The diligence-cost differential is one reason adolescent residential platforms trade at lower multiples than adult residential SUD platforms with equivalent EBITDA scale, despite the higher clinical complexity and acuity.

Integrated care and CCBHC operators

A growing sub-segment that crosses behavioral-health and primary-care delivery is the certified community behavioral health clinic (CCBHC) and integrated FQHC model. CCBHCs receive prospective payment under a state Medicaid framework with federal matching, in exchange for delivering an integrated bundle of mental-health, SUD, primary-care coordination, and crisis services. As of 2026, hundreds of CCBHCs operate across roughly 40 states; CMS continues to expand the model under bipartisan-sponsored legislation. Investor interest in CCBHC operators is modest because the payment model is not optimized for a private-equity exit, but the operating model attracts strategic-buyer interest from FQHC consolidators and managed-care plans. Operators like Compass Health Network in Missouri are positioned at the intersection of these models. The 1115 SUD waiver overlap with CCBHC operation is one of the most under-appreciated geographic variables for behavioral-health platform expansion: state Medicaid managed-care organizations preferentially contract with CCBHC-credentialed providers in many waiver states.

Recent 2024 to 2026 deal flow timeline

Macro: Mertz Taggart Q4 2025 report shows 180 behavioral-health transactions in 2025, slightly up from 176 in 2024. Q1 2025 had 47 transactions (34 M&A), the most since Q4 2022. Q2 2025 had 31 deals. Q3 2025 had 40. Q4 2025 ran approximately 39 (30 M&A plus 9 growth). Sub-sector mix Q4 2025: 27 mental-health deals, 7 addiction-treatment deals, 8 I/DD-Autism deals. Mental health led the year. Addiction-treatment 2025 total: 33 deals, the lowest pace in years. Braff Group Q2 2025 reported 21 of 31 deals as mental health and 9 as addiction (7 M&A plus 2 growth).

February 22, 2024: Acadia acquired Turning Point Centers (Salt Lake City, 76 beds, SUD plus MH). March 2024: Acadia acquired three North Carolina CTCs serving Raleigh, Greenville, Hillsborough. April 16, 2024: Two Chairs Series C $72M. May 2024: US HealthVest refinanced with Capital One $130M (BHB). May 30, 2024: Optum president Heather Cianfrocco detailed Refresh + CARE Counseling wait-time strategy publicly (BHB). June 2024: Talkiatry Series C $130M. June 2024: Done Global founder and clinical president arrested. June 2023 (carryover context): TPG Rise invested in Banyan Treatment Centers.

September 9, 2024: MHPAEA Final Rule issued. September 26, 2024: Acadia $19.85M DOJ False Claims settlement. October 2024: Acadia acquired three South Carolina CTCs. October 2024: Bradford acquired Lakeview Health, Stepping Stones for Recovery, Koru Spring. November 2024: Cerebral $3.65M EDNY non-prosecution agreement.

January 1, 2025: CMS IBH Model cohort 1 awards (Michigan, New York, South Carolina). January 17, 2025: ERIC filed lawsuit against MHPAEA Final Rule; DEA / HHS published telemedicine final rules on buprenorphine and VA continuity-of-care. January 24, 2025: Embark Behavioral Health parted with 3 C-suite members. February 2025: AMFM outcomes report. March 2025: Hazelden Betty Ford / Emory Healthcare partnership announced. April 1, 2025: Two Chairs and SonderMind announced major footprint expansion. May 12, 2025: DOL / HHS / Treasury announced non-enforcement policy for portions of MHPAEA NQTL final regulation. May 2025: Hazelden Betty Ford family-and-children’s-program expansion. June 17, 2025: Banyan acquired former Retreat Behavioral Health facility for $15M.

June 27, 2025: Webster Equity reportedly looking for BayMark sale a second time at marketed EBITDA ~$75M. July 17, 2025: Federal LGBTQI+ Youth Subnetwork shut down. July 2025: Crossroads acquired Family Health Services (2 PA clinics). July 2025: Bradford acquired Last Resort, Crestone Wellness, Chapter House in Texas. October 1, 2025: Section 1115 SUD waiver states required to implement evidence-based individual placement criteria. October 15, 2025: BHB reported Pyramid Healthcare and Advanced Recovery Systems on the market. November 17, 2025: Discovery Behavioral Health replaced longtime CEO. December 5, 2025: Avesi-backed First Steps acquired Georgia Recovery Campus. December 17, 2025: Pinnacle Treatment Centers announced new CEO. December 31, 2025: DEA fourth temporary extension of COVID-19 telemedicine flexibilities through December 31, 2026. December 2025: Done Global systemic-fraud indictment unsealed in SF.

January 13, 2026: SAMHSA announced $231M funding opportunity to administer 988 Lifeline. February 9, 2026: Capital One plus HPS Investment Partners seized control of Discovery Behavioral Health after $280M debt default. February 12, 2026: Talkiatry Series D $210M led by Perceptive Advisors. February 13, 2026: Discovery takeover effective. February 16, 2026: 42 CFR Part 2 final rule enforcement live. February 2026: Bradford acquired Parkdale Center in Indiana. February 27, 2026: Acadia 10-K filed (FY2025 revenue $3.31B). March 20, 2026: FTC Healthcare Task Force launched under Chairman Ferguson per Healthcare Dive. March and May 2026: LifeStance secondary offerings (25M and 35M shares) with concurrent issuer repurchases.

The cumulative pattern: mental-health deal volume sustained, addiction-treatment deal volume at multi-year lows, large-platform sale processes (BayMark, Pyramid, ARS) extending into multi-quarter cycles, and lender-controlled events (Discovery) entering the dataset for the first time in a decade.

Acadia Healthcare deal-by-deal detail

Acadia’s 2024 to 2026 transactional record is the most-detailed public dataset for any platform in the sector because it is reported in the company’s 10-K and 10-Q filings on a deal-by-deal basis. The FY2025 10-K filed February 27, 2026 documents Turning Point Centers (Salt Lake City, 76-bed SUD plus mental-health facility, closed February 22, 2024) as a tuck-in adding both clinical capacity and a Utah footprint that links to Acadia’s existing CTC network across the western United States. The March 2024 acquisitions of three North Carolina comprehensive treatment centers in Raleigh, Greenville, and Hillsborough were structured as a single transaction; the October 2024 acquisitions of three South Carolina CTCs in Clinton, Easley, and Ridgeland followed the same pattern. Both transactions illustrate Acadia’s preferred tuck-in approach: small, contiguous-geography, MAT-focused CTC sites that integrate into the company’s roughly 165-CTC network. Per the 10-K, Acadia closed five facilities (382 beds, mix of four specialty and one acute) in 2025 while adding 1,089 beds, 778 of which came from six de novos. The asymmetric closures-versus-openings pattern is the operational tell of a company optimizing portfolio composition under federal scrutiny rather than expanding indiscriminately. The 2026 plan summarized in BHB September 29, 2025 calls for a $300M capital expenditure reduction, 500 to 700 new beds (down from prior multi-year averages), and additional facility closures as a stated strategic option.

The Department of Justice settlement of $19.85M on September 26, 2024 (DOJ press release) resolved False Claims Act allegations related to medically unnecessary inpatient admissions and length-of-stay practices. The settlement did not resolve the parallel federal investigations referenced in Acadia’s own statement on government inquiries: the SDNY US Attorney’s Office, a Western District of Missouri grand jury subpoena, and a Department of Veterans Affairs Office of Inspector General review. The combination of the settlement, the three open inquiries, and contemporaneous New York Times investigative coverage of admissions and length-of-stay practices in 2024 explains why ACHC trades at a multi-turn discount to UHS BH-segment-implied multiples in 2025 to 2026 despite same-facility revenue growth and continued tuck-in activity.

UHS behavioral segment in detail

UHS’s behavioral-health segment is the cleanest public margin benchmark in the asset class because UHS reports it as a discrete segment with separate same-store and total-facility metrics. Per the Q3 2025 10-Q and the Q3 2025 IR release, the behavioral segment delivered $404.5M same-store adjusted EBITDA in Q3 2025, up 11 percent year over year, at a 22.3 percent margin. Full-year 2025 behavioral EBITDA grew 7.8 percent. Q4 2025 same-facility net revenue rose 7.2 percent and same-facility EBITDA rose 6.9 percent. UHS authorized an incremental $1.5 billion buyback in September 2025. The behavioral segment’s 22.3 percent same-store margin establishes a ceiling for what scaled inpatient psychiatric assets can produce under disciplined operations; private inpatient-psych platforms benchmarking to this number for sale-process underwriting need to evidence comparable workforce density, payer mix, and ancillary-services penetration.

LifeStance, the public outpatient mental-health benchmark

LifeStance Health’s May 2026 8-K and prior filings disclose Q4 2025 revenue of $382.2M, Q4 2025 center margin of $126.3M, and Q4 2025 adjusted EBITDA of $48.8M. Full-year 2025 revenue extrapolates to roughly $1.43B. Q1 2026 revenue reached $403.5M with $22.3M income from operations and $3.144M deal spend on acquisitions. The company’s 2026 guidance puts revenue between $1.615B and $1.655B and adjusted EBITDA between $185M and $205M, with the midpoint adjusted-EBITDA margin around 11.9 percent. The $100M buyback authorization and the two secondary offerings in 2026 (25M shares in March, 35M shares in May) with concurrent issuer repurchases of 7M and 6M shares respectively show that the anchor sponsors (TPG, Summit Partners, Silversmith Capital) are unwinding their positions in coordinated tranches rather than via a single sale. M&A spend remained small ($3.144M Q1 2026 net), which means LifeStance is currently a partial buyer rather than a serial acquirer at platform scale. For private outpatient-mental-health sellers benchmarking against LifeStance, the implied EV / EBITDA multiple at current trading levels has been the lower bound of the platform band, around 9 to 11 times, rather than the higher 12 to 15 times some sponsors expected the parity catalyst to deliver.

Multiples by sub-segment (2025 to 2026)

Public-comp anchors. Acadia Healthcare FY2025 revenue $3.31B with 277 facilities and 12,500 beds; same-facility revenue Q2 2025 +9.5%; Q1 2026 revenue +7.6% YoY (10-Qs at Sept 30, 2025 10-Q). ACHC has traded at depressed multiples relative to UHS BH segment since 2024 federal inquiries. LifeStance 2026 guidance midpoint revenue $1.635B and adj EBITDA $195M imply approximately 11.9% adj EBITDA margin; this anchors the outpatient mental-health platform comp at the lower end of the platform band. Universal Health Services behavioral segment same-store adj EBITDA $404.5M in Q3 2025 (22.3% margin); full-year 2025 BH EBITDA +7.8%; this anchors the inpatient-psych comp at the high end of the platform band.

Private-platform multiple ranges. FOCUS Investment Banking December 2025: platform-tier behavioral-health assets (multi-state, scaled, payer-diversified, accredited) trade at 9 to 15 times EBITDA depending on sub-segment. Mertz Taggart Q4 2025: 2025 multiples stable versus 2023 to 2024 in aggregate but with widening spread, “flight to quality” dynamic. Provident Healthcare Partners Q1 2025 BH update: the multiple-arbitrage drivers are clinician recruitment / retention, geographic density, payer diversification, clinical leadership, and de novo playbook execution.

Sub-segment indicative ranges. Inpatient psych platform: 10 to 13 times EBITDA for scaled ACHC / UHS-comparable assets (MEDIUM). Residential SUD platform: 7 to 11 times EBITDA (MEDIUM); spread widening due to Discovery default, Pyramid + ARS extended sale process, and BayMark second-time-on-market signal. IOP / PHP mental health: 9 to 13 times for clinical-outcomes-driven platforms with payer diversification (MEDIUM). Outpatient mental health: 9 to 12 times EBITDA for private platforms (MEDIUM); LFST trades around the bottom of this band publicly. Telehealth mental health: 2 to 5 times revenue (MEDIUM-LOW); EBITDA multiples not meaningful given profitability profile. Single-site or sub-scale operators: 4 to 6 times EBITDA (MEDIUM), deeper for distressed assets.

Operator-versus-platform spread. Tuck-ins into Acadia, LifeStance, BayMark, BHG, Crossroads, and Bradford typically close in the 4 to 6 times EBITDA band per Mertz Taggart and Braff Group commentary. Platform-level assets that combine accreditation, payer diversification, and clinical leadership routinely trade twice as high. The arbitrage gap, 4 to 6 times acquired into 10 to 13 times platform, is the explicit roll-up thesis cited in the FOCUS December 2025 update. This arbitrage is structural rather than transient; it persists because most independent operators cannot self-fund the credentialing, IT, and clinical-leadership investments required to clear the platform threshold.

Gap: specific publicly attributed transaction multiples for individual 2025 to 2026 deals are largely undisclosed. The ranges above synthesize banker commentary; specific deal-level multiples generally appear only when sponsor exits are announced with disclosed terms, and none of the named platforms above completed a 2024 to 2026 sponsor-to-sponsor exit with disclosed multiples within the verification window.

Payor strategy and commercial reimbursement

Payor mix is the single biggest determinant of platform-tier multiples after EBITDA scale and growth rate. Three commercial-payor structures matter most in behavioral-health platform underwriting.

In-network commercial. Platforms operating in-network with the major commercial plans (UnitedHealthcare, Anthem and Elevance, Aetna, Cigna, Humana, plus Blue Cross Blue Shield licensees by state) report between 35 and 65 percent commercial revenue mix at scale. LifeStance, Refresh, Mindpath, and Sero Mental Health all operate primarily on this model. The advantage is consistent unit economics; the disadvantage is reimbursement rate compression and prior-authorization friction. The MHPAEA Final Rule, fully enforced, would have shifted bargaining power toward providers; the May 12, 2025 pause has deferred that shift.

Medicaid managed care. Platforms with meaningful Medicaid mix (often 30 to 60 percent of revenue) work through state Medicaid managed-care organizations. The contracting cycles are 18 to 36 months and the rate-setting is opaque relative to commercial. Pinnacle, BayMark, BHG, Crossroads, and Spero all carry Medicaid mix in this range. Pinnacle’s New Jersey 2025 addition of Sublocade, Brixadi, and Vivitrol across all locations is an example of a Medicaid-mix-optimized buprenorphine and naltrexone strategy that lifts effective revenue per encounter under state rate structures.

Self-pay and cash. Specialty residential, intensive outpatient, and adolescent programs frequently carry meaningful self-pay percentages because of bed availability, length-of-stay flexibility, and clinical specialization. ERC, Discovery (pre-takeover), Hazelden Betty Ford, Bradford’s professional and clinician programs, and Sandstone Care all carry self-pay mix above sector averages. The advantage is high gross margin per encounter; the disadvantage is volatility and concentration on a smaller population of cash-paying families.

Medicare Advantage is the newest payor lane and the most under-modeled. CMS expanded Medicare behavioral-health coverage in 2025 (CMS) with new safety-planning codes, digital MH device coverage, and expanded telehealth. Medicare Advantage plans contract for behavioral services with increasing supplemental benefits over the next 18 to 36 months. Platforms with senior populations or 65-and-over service-line capacity have an asymmetric upside not yet priced into platform-tier multiples.

Diligence playbook: what changed in 2024 to 2026

Quality-of-earnings work on behavioral-health assets has expanded in scope and depth over the 24-month verification window. Five new diligence workstreams have moved from optional to mandatory.

First, controlled-substance prescribing audits. Buyers now request a 36-month prescriber-by-prescriber log of Schedule II to V controlled substances by state, mapped against DEA registration status, in-state telemedicine practice acts, and any DOJ or state attorney general subpoenas. This audit is the direct downstream of the Cerebral and Done outcomes and applies to outpatient mental-health, psychiatry, and OUD platforms, not only telehealth-native operators.

Second, 42 CFR Part 2 compliance. Buyers request EHR configuration documentation showing how SUD counseling-note flags are enforced, a sample re-disclosure log, a written compliance policy aligned to the February 16, 2026 enforcement effective date, and an attestation that the platform has run at least one internal Part 2 audit since enforcement live. The audit cost at platform scale is modest; the risk of a misconfiguration discovered post-close is meaningful.

Third, MHPAEA NQTL exposure. Even with the May 12, 2025 enforcement pause, commercial-payer plans continue to issue NQTL comparative-analysis requests. Buyers request the platform’s prior-authorization volume, denial rates, and appeal-win rates by payer for at least 24 months, plus copies of any payer-NQTL audits. Platforms with low denial rates and high appeal-win rates demonstrate parity-friendly utilization-management practices and command a premium.

Fourth, 988 and crisis-services contract status. For platforms with crisis or stabilization-services offerings, buyers request federal and state contract status under 988-related funding and any opioid-settlement-fund recipient contracts. The $231M January 2026 SAMHSA administrator funding opportunity (SAMHSA) and the underlying state-fee revenue streams add a public-funding layer that is durable but procurement-heavy.

Fifth, Section 1115 waiver alignment. Buyers ask whether the platform operates in 1115 SUD or SMI waiver states and how its in-network contracts price the IMD payment flexibility. Platforms operating in non-waiver states that overlap with high-need populations face a Medicaid revenue ceiling that disciplined buyers price into the model.

The cumulative effect of these five workstreams is to lengthen diligence cycles by approximately 30 to 60 days on platform-tier processes and to surface adjustments to the indicated EBITDA that did not appear in 2020 to 2023 cycle precedent transactions. Disciplined sellers prepare these workstreams pre-LOI, ideally with banker assistance, to compress the buyer’s drag on the process.

Sponsor concentration map

Two sponsors hold the largest behavioral-health platform-portfolio concentrations as of mid-2026. The Vistria Group holds Behavioral Health Group (acquired October 2022 from Frontenac), Sandstone Care (acquired June 2022 from Fund IV), and Advanced Recovery Systems per BHB October 15, 2025 reporting. Nautic Partners holds Pyramid Healthcare (acquired 2021), Odyssey Behavioral Health, Sagent (formerly Nystrom & Associates), and Advantage Healthcare Services. The two firms have a combined seven behavioral-health platforms by our count, spanning OUD outpatient, adolescent SUD, residential SUD, inpatient mental health, outpatient mental health, and behavioral pharmacy.

Sponsor concentration matters for two reasons. First, multi-platform sponsors can run sponsor-internal cross-platform tuck-ins that compress the addressable buyer pool for any single platform’s tuck-in candidates. A solo outpatient mental-health practice in a Vistria or Nautic geography may be quietly absorbed into a sister platform rather than auctioned to the broader buyer pool. Second, sponsor-concentration risk informs limited-partner allocation discipline; the LPs of the most active sponsors are increasingly aware that “behavioral health” is no longer a niche allocation but a sector concentration that warrants its own portfolio-construction conversation.

Second-tier sponsor concentrations include TPG (Banyan via TPG Rise; LifeStance as anchor block public ownership), Webster Equity Partners (BayMark plus historical Discovery), and Linden Capital Partners (Pinnacle plus historical Smile Doctors and adjacent platforms outside behavioral). The TPG dual position in LifeStance and Banyan creates a public-private behavioral pairing that no other sponsor matches in 2026.

Six contrarian findings

1. Optum owns the largest US outpatient MH platform via Refresh, and the market still mistracks this

Optum acquired Refresh Mental Health from Kelso & Company in early 2022. The 300-plus-site network across 37 states with 1,500-plus employees remains under Optum throughout 2024 to 2026 per May 30, 2024 BHB. The largest scaled outpatient mental-health asset in the country cannot be acquired by a financial sponsor, which compresses the addressable buyer pool for platform-tier outpatient mental-health exits and biases the sponsor-to-sponsor exit assumption downward.

2. MHPAEA rerate is stalled by the May 12, 2025 enforcement pause; private MH multiples should have moved but have not

The September 9, 2024 final rule was the catalyst for an expected upward repricing of in-network outpatient mental-health platform valuations. The May 12, 2025 non-enforcement statement deferred the catalyst. Mertz Taggart Q4 2025 shows multiples stable rather than expanding, with valuations widening between premium and distressed assets. The parity-driven rerate remains an option-not-a-fact through at least 2026.

3. Cerebral and Done DOJ outcomes have permanently raised the legal-risk premium on telehealth MH PE

The Cerebral EDNY November 2024 non-prosecution agreement (Healthcare Dive) plus Done’s June 2024 arrest and December 2025 systemic-fraud indictment (Fierce Healthcare) have shifted underwriters and sponsors to treat controlled-substance prescribing via telehealth as a securities and criminal-risk matter rather than a clinical-quality matter. This is a permanent shift in due-diligence depth, not a transient PR cycle (see Ropes & Gray analysis).

4. Discovery Behavioral Health’s lender takeover signals the limits of the tri-modality thesis

Webster Equity’s more-than-13-year hold on Discovery Behavioral Health ended via a $280M debt default and Capital One plus HPS Investment Partners takeover effective February 13, 2026, with the board dismissed. The takeover is the first 2020s public sign that the “tri-modality” (mental health + SUD + eating disorder) platform thesis has practical limits. Two other tri-modality assets (Pyramid Healthcare, Advanced Recovery Systems) are approaching similar pressure points per BHB October 2025.

5. Hazelden Betty Ford is the most under-tracked active consolidator in adult SUD

First-half 2024 revenue $119.2M (+11.3% YoY) per BHB August 21, 2024. Betty Ford Center 240-bed expansion completing 2025; Emory Healthcare partnership March 2025; family-and-children’s-program expansion May 2025. As a 501(c)(3), Hazelden Betty Ford is invisible to the standard PE tracker but is selectively consolidating inpatient capacity and the clinical workforce-training pipeline in ways that crowd out for-profit residential players. Form 990s at ProPublica.

6. ACHC’s BH-segment margin gap to UHS BH (22.3%) shows asset-class economics intact behind governance noise

UHS behavioral segment Q3 2025 same-store adjusted EBITDA $404.5M at a 22.3% margin with +11% same-store growth per the 10-Q. ACHC’s discount to UHS reflects governance, regulatory, and reputational risk (DOJ settlement, three federal inquiries, NYT investigative coverage) rather than sector fundamentals. The gap creates a contrarian valuation argument for the asset class once Acadia-specific risks resolve. The inpatient-psych unit economics demonstrated by UHS are intact.

Bonus finding: opioid-settlement-fund flows are an under-modeled revenue layer for OUD platforms

The $57.7 billion National Opioid Settlement pool (CRS LSB11270) is now flowing to state and county recipients on a multi-year basis. Most state allocation plans direct 60 to 70 percent of disbursed funds to treatment-related uses including MAT and MOUD capacity. For OUD platforms with state and county contracting capability (BayMark, Crossroads, Pinnacle, Spero, Pathway, BHG), this is a non-trivial commercial revenue layer that did not exist in 2019 and is in many cases not modeled in 2020-vintage diligence underwriting. Platforms with multi-state footprints and existing contracting infrastructure can absorb settlement-funded contracts in the 5 to 15 percent of revenue range over the next 36 months. Disciplined acquirers are now including a settlement-funded revenue line as a discrete addition to the diligence model with appropriate run-rate disclosures and contract-by-contract documentation.

Bonus finding: 988 crisis-services infrastructure is the next federally seeded growth lane and remains under-penetrated by PE

Crisis stabilization, mobile crisis response, and 23-hour crisis observation are the three operating models that map directly to 988 Lifeline contact volume. With more than 8 million 988 contacts in 2025 (NAMI) and 12 states having enacted a recurring 988 telecom fee plus 5 states with recurring state appropriations as of June 2025, the federal-plus-state funding base for crisis services is now substantial. Yet most crisis-services capacity remains in nonprofit, county, or hospital ownership rather than PE-platform hands. The opportunity for a sponsor-led crisis-services platform play is real but constrained by the reimbursement model: most 988 funding is non-fee-for-service grant or per-capita allocation, which compresses the discounted-cash-flow economics that sponsors rely on for underwriting. Sponsors that can build a hybrid model combining 988-funded crisis work with downstream IOP / PHP and outpatient bookings have a structural opportunity that is currently unfilled.

Workforce, the structural bottleneck

The Bureau of Labor Statistics Occupational Outlook Handbook reports the median annual wage for substance-abuse, behavioral-disorder, and mental-health counselors was $59,190 in May 2024. The 10th-percentile wage was under $39,090; the 90th-percentile wage was over $98,210. Projected employment growth was 17 percent from 2024 to 2034 (“much faster than average”), with about 48,300 openings per year on average over the decade.

HRSA Bureau of Health Workforce data show demand exceeds supply by 8,504 active psychiatrists, the number that would erase all mental-health Health Professional Shortage Area (HPSA) designations (HRSA fact sheet). Roughly 47 percent of the US population (158 million people) lives in a mental-health workforce shortage area (HRSA dashboard; KFF). Only 36 percent of psychiatrists accept new Medicaid patients on average, well below the 71 percent rate for physicians on average (KFF).

The Professional Counselor Licensure Compact has been enacted in 39 states plus DC, making it the largest mental-health interstate compact in US history per the American Counseling Association. Privileges to practice began issuing September 30, 2025 in Minnesota and Arizona; Ohio joined January 5, 2026 (NGA; Counseling Compact news). Eleven states show no current Professional Counselor Licensure Compact activity as of late 2025. The Social Work Compact crossed the 7-state threshold for activation in 2024.

Why workforce is the throttle: at platform scale, the binding constraint on adding revenue is not capital, real estate, or licensure. It is credentialed clinicians who will accept the platform’s payer mix and supervisory structure. Acadia’s 2025 closure of 5 facilities representing 382 beds, while opening 778 beds via 6 de novos, illustrates the reallocation pattern: capital flows to geographies where workforce supply is available, not to where capital alone can build. The Counselor Compact and the still-pending psychologist and LCSW compacts are the most consequential medium-term variables for platform growth velocity.

Compensation pressure is real but uneven. Outpatient mental-health platforms competing for psychiatrists in metros where commercial reimbursement supports six-figure cash-only practices have to offer a combination of in-network panel access, supervisory load, productivity bonuses, retirement contributions, and ownership-track equity to retain clinicians at scale. Hospital-based behavioral programs operating under acute-care collective-bargaining structures face a different compensation curve. The platforms with the lowest clinician turnover in 2025 reporting (LifeStance, Refresh, Talkiatry under its full-stack in-network model, Two Chairs) share a structural feature: published clinician compensation ranges with documented productivity bands, plus operational support that removes administrative work from clinician hours. Platforms that retain clinicians at this level command a multiple-turn premium in sale-process outcomes.

Workforce pipeline development is a competitive moat. Hazelden Betty Ford’s Graduate School of Addiction Studies, the most-established master’s-level addiction-counseling pipeline in the country, illustrates the model: a clinical pipeline tied to the platform’s own service-delivery infrastructure produces graduates who are pre-credentialed to the platform’s clinical standards. For-profit platforms have largely not invested in equivalent training infrastructure; the workforce pipeline gap is among the structural reasons the nonprofit segment outperforms in long-term retention metrics.

Seller-fit matrix

Match the buyer pool to the seller profile before letter-of-intent stage. Solo and sub-scale operators are typically best matched to in-state strategic buyers (FQHC, hospital outpatient, regional aggregator) for SDE-based transactions, while $5M-plus EBITDA assets benefit from a broader sponsor-led process. The middle band, $2M to $8M EBITDA, is where banker representation produces the largest multiple lift.

Two practical recommendations for sellers preparing in 2026. First, run a pre-process scrub at least 9 to 12 months before going to market. The five new diligence workstreams documented above (controlled-substance audit, 42 CFR Part 2 compliance, MHPAEA NQTL exposure, 988 and settlement-fund contract status, 1115 waiver alignment) take meaningful internal effort to assemble cleanly. Selling into 2026 multiples requires entering the process with these workstreams already complete. Second, document clinician-retention economics with primary data. Sellers who can show 24 to 36 months of clinician compensation history, productivity bands, retention cohorts, and turnover by service-line evidence the operating discipline that platform-tier buyers will pay a premium for. Sellers who cannot produce this data tend to settle at the lower bound of their applicable multiple range.

Specialty-asset profiles: ERC, BHG, BayMark, and Talkiatry

Four named platforms warrant additional analysis because each represents the dominant operator in its sub-segment and each is a useful anchor for benchmarking adjacent assets.

Eating Recovery Center / Pathlight Mood & Anxiety (Apax + Oak HC/FT)

ERC operates as the largest integrated eating-disorder provider in the United States, with approximately 30 centers and a substantial virtual-care footprint. The platform combines residential, partial-hospitalization, intensive-outpatient, outpatient, and virtual modalities under a single clinical framework. Pathlight Mood & Anxiety is the affiliated platform serving mood and anxiety populations, often co-located with ERC sites for clinical complementarity. Apax Funds and Oak HC/FT acquired ERC from CCMP Capital in October 2021 for $1.4B per Apax press release. There has been no public sale process across the 2024 to 2026 window. ERC’s clinical-outcomes infrastructure (published research, in-network commercial-payer contracting, accreditation across Joint Commission and CARF) makes it the asset-class benchmark for specialty-eating-disorder valuation. Sponsors evaluating sub-scale eating-disorder platforms benchmark against ERC’s vertical integration and length-of-stay management practices.

Behavioral Health Group / BHG (Vistria)

BHG is the largest Joint-Commission-accredited OUD outpatient network in the country, operating 116 facilities and 2 labs across 23 states as of late 2025. Vistria Group acquired BHG from Frontenac in October 2022 per Frontenac’s release; under Vistria, BHG acquired the Center for Behavioral Health (CBH). BHG’s accreditation profile and clinical-quality investment is the operating model that the Health Affairs February 2025 study (Health Affairs) referenced when concluding that PE-acquired OTPs did not measurably reduce market-level methadone supply. The PE-owned OUD model, at BHG scale, sustains supply while shifting governance, payer contracting, and EHR infrastructure. The valuation implication: BHG-class assets command a premium because the accreditation infrastructure is hard to replicate at smaller scale.

BayMark Health Services (Webster Equity)

BayMark is the largest single OTP operator in the United States with 102 OTPs across 28 states and 280-plus total facilities serving approximately 23,000 patients per day. Webster Equity Partners (with BPEA co-invest) acquired BayMark in 2015; the platform has held under Webster for more than a decade. BHB June 27, 2025 reported Webster’s second-attempt sale of BayMark at marketed EBITDA of approximately $75M, implying a likely transaction enterprise value in the $600M to $900M range depending on multiple negotiation. BayMark’s 2024 to 2025 transactional history includes the Kaden Health telehealth-OUD acquisition and the Riverwood Group OTP roll-up (BayMark blog). The Senate Markey / Braun PE OTP inquiry of March 2024 (press release) named BayMark among recipients; the inquiry has not been resolved as of mid-2026 and is part of why the second-attempt sale process has run multiple quarters.

Talkiatry (Andreessen Horowitz + Perceptive Advisors)

Talkiatry operates the largest US full-stack in-network virtual psychiatry platform. The full-stack model bundles credentialing, billing, prior-authorization, EHR, supervision, and clinical operations under a single technology platform, with psychiatrists employed rather than contracted. The June 2024 Series C of $130M (PRNewswire) was led by Andreessen Horowitz with Perceptive Advisors and Banc of California debt. The February 12, 2026 Series D of $210M (PRNewswire) was led by Perceptive Advisors and was oversubscribed. Cumulative raise exceeds $400M. The structural differentiator for Talkiatry against the post-Cerebral and post-Done risk standard is the in-network full-stack employed-psychiatrist model and the deliberate non-emphasis on direct-to-consumer stimulant prescribing. Stat News February 12, 2026 covered the round and the platform’s stated AI investment plan for psychiatrist clinical-decision support.

Federal enforcement posture and what it means for 2026 to 2027 deal flow

The federal enforcement posture toward private equity in healthcare hardened measurably from March 2024 through the first half of 2026. The FTC plus DOJ plus HHS cross-government PE / healthcare inquiry of March 2024 and the FTC plus DOJ serial-acquisitions RFI of May 2024 opened a longer-term tracking infrastructure that did not exist before 2024. The Biden administration era closed with active oversight at the agency level; the Trump administration’s FTC Healthcare Task Force launched March 20, 2026 under Chairman Ferguson reframed but did not retire the federal attention on roll-up strategies in healthcare services. Behavioral health, specifically the OUD and adolescent residential sub-segments, sits inside the highest enforcement-risk band given the combination of vulnerable-population concerns, federal reimbursement dependency, and the Senate Markey / Braun PE OTP inquiry’s continued visibility.

Practical effect for sponsors: filings under the Hart-Scott-Rodino Act for behavioral-health platform transactions now carry meaningfully longer second-request risk than in 2018 to 2022 transactions of similar size. The State of New York’s amended General Business Law healthcare-transaction notification statute, the California AB 3129 review framework (Health Care Authority oversight, signed 2024), and similar Oregon and Connecticut review structures add state-level review on top of federal review. Platforms with a clear roll-up history (BayMark, Acadia CTC unit, Crossroads, BHG, Pinnacle) face the heaviest scrutiny under serial-acquisition theory, which the May 2024 RFI specifically invited industry comment on. The reality on the ground is that platform-tier transactions now incorporate antitrust counsel into the LOI-stage workflow rather than the closing-condition workflow, and timing-to-close expectations have stretched from 60 to 90 days to 90 to 150 days for healthcare-services platform transactions of $250M-plus enterprise value.

State-attorney-general activity matters separately. Multiple state attorneys general have intervened in behavioral-health transactions or post-close conduct since 2024, with documented matters in Pennsylvania, Massachusetts, California, Oregon, Washington, and New York. Sponsors with multi-platform behavioral exposure should expect cross-state coordination of state-AG action by 2027 as the National Association of Attorneys General behavioral-health workstream matures.

Limitations of this analysis

The research brief flagged several items that we could not verify to primary sources within the 2024 to 2026 window. We carry those gaps forward here so readers know where the analysis is durable and where it depends on banker commentary or trade-press synthesis.

Pyramid Healthcare = Wellspring Capital: NOT supported. Primary sources show Nautic Partners acquired Pyramid in 2021. We use Nautic and embed the correction as a contrarian finding. Eating Recovery Center = CCMP plus Trilantic: NOT supported in 2024 to 2026. CCMP exited in October 2021. Current sponsors are Apax Funds plus Oak HC/FT. Refresh Mental Health = Kelso & Company: historically correct (December 2020 acquisition at ~$700M) but Kelso sold to Optum in early 2022. Praxis Health (Lindsay Goldberg, mental health): Lindsay Goldberg’s MH portfolio is Refresh (exited 2022) and Sero Mental Health (current). Praxis Health in Oregon does not appear to be LG-owned in primary search. Sandstone Care = Greenbriar Equity: NOT supported. Vistria Group invested June 2022. Embark Behavioral Health = Flexpoint Ford: NOT supported. Consonance Capital Partners acquired late 2022. Springstone = Petra Capital: NOT supported. Lifepoint Health (Apollo) acquired Springstone in 2021; Petra runs separate Acute Behavioral Health platform. Pathway Healthcare = Bain Capital: not corroborated in this primary-source pass; PitchBook confirmation recommended. Bradford Health Services = BlueMountain or Five Mile: historical Centre Partners ownership confirmed; current owner is Lee Equity plus Constitution Capital (Lee acquired majority from Centre in 2022). Magnus Health, Pennsylvania Counseling Services, AspenRidge Recovery, Restore Wellness, Brightside Behavioral Health, and Hospital Sisters Health System behavioral footprint were not addressed in this pass. Spero Health = Goldman Sachs: GS sponsorship is widely cited historically but not corroborated by a 2024 to 2026 primary press release in this pass; PitchBook or direct GS Merchant Banking verification recommended. Brave Health 2024 to 2026 round: not found in primary search; the last documented round is October 2022. Specific transaction multiples for 2024 to 2026 platform deals are not publicly disclosed; the multiple ranges in this tracker are banker-published synthesis, not deal-disclosed. 2024 to 2026 line-item federal behavioral-health spending as a single CMS series does not exist; the macro section uses NHE topline plus state-level Medicaid commentary. Two Chairs December 2025 Series D was rumored but not announced as of last verified press cycle.

Related CT Acquisitions research

For cross-sector PE roll-up context: private equity platforms by sector 2026 (cross-sector platform map across healthcare, services, industrials, and consumer). For closely adjacent healthcare-services trackers: private equity veterinary 2026, private equity dermatology 2026, dental DSO PE roll-up tracker 2026, and the closest sibling, home health PE roll-up tracker 2026. For roll-up context outside healthcare: manufacturing PE roll-up tracker 2026. For sell-side practitioner guides: how to sell a behavioral health practice and how to sell an addiction treatment center. For valuation methodology: healthcare business valuation.

Sources and methodology references

SEC EDGAR filings. Acadia Healthcare FY2025 10-K filing; Q3 2025 10-Q filing; Q2 2025 10-Q filing; investor news company statement. LifeStance Health 8-K filings on SEC EDGAR; February 2026 8-K; May 2026 8-K. Universal Health Services Q3 2025 IR release; Sept 30 2025 10-Q.

Federal Register. MHPAEA Final Rule (89 FR 77586, Sept 23, 2024). Fourth Temporary Extension of COVID-19 Telemedicine Flexibilities (Dec 31, 2025). 42 CFR Part 2 final rule (89 FR 12472, February 16, 2024).

SAMHSA and N-SUMHSS. 2024 NSDUH annual national report. 2024 N-SUMHSS annual report. 2024 National Directory of Mental Health Treatment Facilities. NSDUH 2024 press release. $231M 988 administrator funding announcement (Jan 2026).

CMS, 1115 waivers, and the IBH Model. CMS NHE 2024 Fact Sheet. CMS Behavioral Health Strategy. CMS IBH Model. NACo IBH summary. Commonwealth Fund analysis. CMS blog on 2025 Medicare BH coverage changes. Moss Adams summary.

DOJ and FTC press releases. DOJ Acadia $19.85M False Claims settlement (Sept 26, 2024). DOJ Done Health founder arrest (June 2024). FTC + DOJ + HHS cross-government PE / healthcare inquiry (March 2024). FTC + DOJ serial-acquisitions RFI (May 2024). FTC Healthcare Task Force launch (March 20, 2026).

DOL and EBSA. MHPAEA Final Rules fact sheet. May 12, 2025 non-enforcement statement.

HRSA, KFF, and Commonwealth Fund. HRSA Behavioral Health Workforce Projections fact sheet. HRSA shortage-areas dashboard. KFF Medicaid MH and SUD expansion brief. KFF Medicaid waiver tracker. KFF state options brief. KFF mental-health HPSA indicator. KFF strategies brief.

Sponsor portfolio pages. Nautic Partners. Webster Equity Partners (BayMark). Apax (ERC). Vistria (Sandstone). Vistria (BHG). Linden Capital Partners. Revelstoke Capital Partners. Lindsay Goldberg (Sero). TPG Rise (Banyan). New Heritage (AMFM). Avesi Partners. Lifepoint Health. Lee Equity Partners.

Industry data and trade press. Mertz Taggart Q4 2025 BH M&A report; BHB Q1 2025 deal volume report; BHB pre-pandemic levels piece; BHB 2025 full-year wrap. FOCUS Investment Banking BH EBITDA multiples. Braff Group Q2 2025 update. Provident Healthcare Partners Q1 2025 BH update. Capstone pediatric BH M&A update.

Research and advocacy. Health Affairs February 2025 PE OTP study. PE Stakeholder Project July 2025 acquisitions. PESP PE-owned SUD false-claims. PESP closures and layoffs. Senate Markey / Braun OTP letter (March 2024).

NABH, NAMI, ACA, NGA, Counseling Compact. NABH IMD Exclusion fact sheet. NAMI 988 page. NAMI 988 state legislation map. NAMI 2024 state-legislation brief. ACA Counseling Compact. NGA Understanding Behavioral Health Compacts. CRS Opioid Litigation report. CRS IMD report.

CDC NCHS and BLS. CDC NCHS Data Brief No. 509 (Sept 2024). NCHS Blog on 2023 final suicide data. BLS OOH counselors page.

FCC and DEA. FCC 988 page. DEA telemedicine extension press release (Dec 31, 2025). Holland & Knight analysis. McDermott+.

Frequently asked questions

How many US behavioral health PE platforms are active in 2026?

Twenty-eight active private-equity-backed platforms are tracked in this analysis across inpatient psychiatric, residential SUD, outpatient mental health, IOP / PHP, eating disorders, OUD / MAT, telehealth mental health, and pediatric / adolescent mental health. The figure excludes ABA / autism (separate forthcoming tracker), I/DD consolidators, and pure consumer-app companies. Mertz Taggart’s Q4 2025 BH M&A report counts 180 transactions across the sector in 2025, of which the platform-level subset is a small fraction.

Who owns the largest outpatient mental health platform?

UnitedHealth Group’s Optum, via Refresh Mental Health, with 300-plus sites across 37 states and 1,500-plus employees. Optum acquired Refresh from Kelso & Company in early 2022 (BHB May 30, 2024). It is a strategic, not a PE platform.

Did Cerebral resolve its DOJ exposure?

Partially. Cerebral entered a $3.65 million non-prosecution agreement with the EDNY US Attorney’s Office in November 2024 over allegations of encouraging Adderall over-prescription between 2019 and 2022 (Healthcare Dive). A separate $7M FTC / DOJ settlement resolved earlier user-data and cancellation-practice allegations. Founder Kyle Robertson civil litigation remains active.

What is the typical EBITDA multiple for a $2M outpatient mental-health platform in 2026?

Mid-band: 5 to 8 times EBITDA per FOCUS Investment Banking and Mertz Taggart commentary, depending on payer mix, clinician retention, and clinical-outcomes documentation. Platform-tier outpatient mental-health assets (over $20M EBITDA) trade at 9 to 12 times EBITDA, with LifeStance public as the bottom-of-band anchor.

How does the Mental Health Parity Final Rule affect MH practice valuations?

In principle, the September 9, 2024 final rule should have pushed in-network commercial reimbursement higher and compressed prior-authorization friction, lifting outpatient mental-health multiples. In practice, the Departments’ May 12, 2025 non-enforcement statement deferred the catalyst, and 2025 multiples per Mertz Taggart Q4 2025 were stable rather than expanding.

Which sponsors are most active in 2024 to 2026 behavioral health?

By number of platforms held simultaneously: Nautic Partners (Pyramid, Odyssey, Sagent, Advantage Healthcare Services) and Vistria Group (BHG, Sandstone, Advanced Recovery Systems). By transaction volume across 2024 to 2026: Bradford Health Services (Lee Equity), Crossroads (Revelstoke + CDPQ), Banyan (TPG Rise), Acadia (public). By new-platform formation: TPG Rise (Banyan, 2023), Apax + Oak HC/FT (ERC, 2021 carried forward), Consonance Capital (Embark, 2022).

What happened to Pyramid Healthcare’s sponsorship?

Pyramid Healthcare is held by Nautic Partners, which acquired the platform in 2021. The brief request named Wellspring Capital, but primary sources do not support Wellspring as the current sponsor. The platform is reportedly on the market alongside Advanced Recovery Systems per BHB October 15, 2025.

What is the difference between Springstone and Acute Behavioral Health Group?

Springstone is owned by Lifepoint Health (the Apollo-controlled hospital operator), which acquired Springstone from Welsh, Carson, Anderson & Stowe and others in 2021 for $250M (Becker’s BH). Springstone operates 18 behavioral hospitals plus 35 outpatient locations across 9 states. Acute Behavioral Health is a separate platform owned by Petra Capital Partners, focused on pediatric / adolescent inpatient and outpatient, which acquired Hallmark Youthcare in July 2022 (Capstone Partners pediatric BH M&A update).

Who is buying small SUD treatment centers (under $2M EBITDA)?

The active acquirer pool for sub-$2M EBITDA SUD assets includes Bradford Health Services (Lee Equity), BayMark (Webster), Pinnacle (Linden), Banyan (TPG Rise), Pathway Healthcare, First Steps (Avesi), and regional sponsor-backed aggregators. Tuck-in multiples sit in the 4 to 6 times EBITDA band per Mertz Taggart and Braff Group commentary. Hazelden Betty Ford as a nonprofit selectively absorbs assets that fit its clinical model.

How does the 988 Lifeline rollout affect crisis-services M&A?

988 received more than 8 million contacts in 2025 per NAMI; SAMHSA issued a $231M January 2026 administrator funding opportunity; 12 states had enacted a recurring 988 telecom fee as of June 2025. Crisis-services M&A is still nascent at platform scale, but the federal and state funding flow supports public-private partnerships that can be integrated with FQHC, CCBHC, and CMHC operators. Compass Health Network in Missouri is one operating example.

When does the next CMS IBH cohort open?

Cohort 1 was awarded January 1, 2025 to Michigan, New York, and South Carolina. CMS plans up to 8 states across the life of the seven-year model, with up to $7.5M per state (CMS IBH page). Cohort 2 and subsequent cohort timing has not been announced as of June 2026; the Commonwealth Fund’s 2025 strategy analysis is the best public discussion of subsequent cohorts.

How often is this tracker updated?

Quarterly. The next scheduled refresh is September 16, 2026, and we trigger an off-cycle refresh on any material sponsor transition, public-comp earnings event, or federal regulatory milestone (DOJ settlement, parity-rule enforcement update, or DEA telemedicine rule change).

About the author and CT Acquisitions

This tracker is written and maintained by Christoph Totter (LinkedIn), founder of CT Acquisitions. CT Acquisitions advises owners of healthcare-services and other middle-market businesses on exit planning, valuation, and buyer selection across private-equity, strategic, and family-office buyer pools. If you operate a behavioral-health practice or platform and are evaluating an exit, refinancing, or growth-equity recapitalization in 2026, you can reach the team via contact-us.

Last updated: June 16, 2026. CT Acquisitions refreshes this tracker quarterly. Next refresh: September 16, 2026 OR upon next material sponsor transition.